Skip to content

Clinical Evaluation of Cast21 Short Arm Product During Treatment of Distal Radial or Distal Ulnar Fractures

Clinical Evaluation of Cast21 Short Arm Product During Treatment of Distal Radial or Distal Ulnar Fractures

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06304649
Acronym
Cast21 SAP
Enrollment
60
Registered
2024-03-12
Start date
2024-04-30
Completion date
2024-12-31
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture, Fractures, Fractures Bone, Fractures, Closed, Radius Distal Fracture, Radius; Fracture, Lower or Distal End, Ulna Fractures

Brief summary

The primary objective of this study will be the collection of preliminary clinical evidence to indicate that Cast21 Short Arm Product is no worse than the current standard of care arm immobilization devices in pediatric patients. A secondary objective will be to characterize the clinician and patient experience with the Cast21 Short Arm Product.

Interventions

DEVICECast or brace alternative

Waterproof alternative to a cast or brace for broken bones

Sponsors

Cast21
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Demographic characteristics: all persons ages 3 and above, regardless of the race and sex will be eligible to participate in this study * Medical condition: participants must present with a closed, nondisplaced, or minimally displaced distal radius fracture and/or distal ulnar fracture that does not require a bone reduction procedure within 10 days from the date of injury * Sizing: participants eligible for the Cast21 Short Arm Product must undergo sizing conducted by the clinical staff to ensure fit into one of the products (sizes XS-L)

Exclusion criteria

* Participants requiring a surgical intervention * Participants with moderately displaced or angulated fractures or fractures requiring a bone reduction procedure. * Participants with a known history of bone diseases e.g. osteogenesis imperfecta or other pathologic bone conditions * Participants with pathologic fractures e.g., presence of bone cyst * Participants who smoke * Participants with pre-existing skin infection or condition of the lower arm (participants exhibiting only minor skin abrasions, lacerations, or skin condition might be eligible per clinical investigator's discretion)

Design outcomes

Primary

MeasureTime frameDescription
Clinical determination of healing (standard of care)At treatment completion, an average of 4 weeksA binary determination of healing after the intervention will be asserted by the clinician
Range of Motion (standard of care)At treatment completion, an average of 4 weeksClinicians will asses patients for a binary determination of Full Range of Motion or Limited Range of Motion

Secondary

MeasureTime frameDescription
Patient Reported Outcomes - PainBefore treatment (0 Days) and at treatment completion, an average of 4 weeksPatient pain scores with the Wong-Baker FACES Pain Rating Scale will be assessed. The rating scale is 1 (min) to 10 (max) with lower scores being a better outcome.
Patient Reported Outcomes - SatisfactionAt treatment completion, an average of 4 weeksA questionnaire adapted from the Patient-Reported Outcomes Measurement Information System (PROMIS) scale will be administered. The scale is 1 (min) to 5 (max), with high scores indicating a better outcome.
Physical Therapy ReferralAt treatment completion, an average of 4 weeksA binary referral to physical therapy as part of the standard of care will be observed if the patient's range of motion (see Primary Outcome 2) is such that the clinician will refer more care.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026